Clinical experiment designed to assess clinical efficacy targeting AHR/BDNF/CLDN1 in human. Primary outcome: Validate Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Intervention
Description
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Intervention
Background and Rationale
Parkinson's disease (PD) affects over 10 million people worldwide, with mounting evidence supporting the gut-brain axis as a critical pathway in disease pathogenesis. Recent studies demonstrate that α-synuclein pathology begins in the enteric nervous system years before motor symptoms manifest, suggesting that gut microbiome dysbiosis may trigger the cascade leading to neurodegeneration. This longitudinal clinical study investigates the mechanistic relationship between gut microbiome composition, α-synuclein misfolding, and PD progression, while evaluating targeted microbiome interventions as potential disease-modifying therapies. The study employs a multi-phase design combining observational cohort analysis with randomized controlled intervention trials. We will recruit 400 participants across the PD spectrum: prodromal PD patients with REM sleep behavior disorder, early-stage PD patients (Hoehn & Yahr stages 1-2), and age-matched healthy controls....
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Intervention
Background and Rationale
Parkinson's disease (PD) affects over 10 million people worldwide, with mounting evidence supporting the gut-brain axis as a critical pathway in disease pathogenesis. Recent studies demonstrate that α-synuclein pathology begins in the enteric nervous system years before motor symptoms manifest, suggesting that gut microbiome dysbiosis may trigger the cascade leading to neurodegeneration. This longitudinal clinical study investigates the mechanistic relationship between gut microbiome composition, α-synuclein misfolding, and PD progression, while evaluating targeted microbiome interventions as potential disease-modifying therapies. The study employs a multi-phase design combining observational cohort analysis with randomized controlled intervention trials. We will recruit 400 participants across the PD spectrum: prodromal PD patients with REM sleep behavior disorder, early-stage PD patients (Hoehn & Yahr stages 1-2), and age-matched healthy controls. Key measurements include comprehensive microbiome sequencing, fecal and plasma α-synuclein quantification, vagus nerve imaging via high-resolution MRI, dopaminergic function assessment through DaTscan, and detailed clinical phenotyping using standardized scales. The intervention phase tests precision microbiome therapy using personalized probiotic formulations designed to restore beneficial bacterial strains known to promote α-synuclein clearance. Innovation lies in the integration of cutting-edge multi-omics approaches with real-time biomarker monitoring to establish causal relationships between gut dysbiosis and neurodegeneration. This study has profound implications for PD prevention and treatment, potentially identifying individuals at risk before irreversible neuronal loss occurs and providing the first targeted microbiome-based therapy for neurodegenerative disease. Success would revolutionize our understanding of PD etiology and establish a new paradigm for early intervention strategies.
This experiment directly tests predictions arising from the following hypotheses:
Gut Barrier Permeability-α-Synuclein Axis Modulation
Enteric Nervous System Prion-Like Propagation Blockade
Phase 1 (Months 1-12): Recruit and characterize 400 participants (n=150 prodromal PD, n=150 early PD, n=100 controls). Collect baseline fecal samples for 16S rRNA and metagenomic sequencing using Illumina NovaSeq platform. Quantify α-synuclein levels in stool and plasma via Simoa ultrasensitive immunoassays. Perform structural and functional MRI including vagus nerve tractography and substantia nigra neuromelanin imaging. Conduct DaTscan SPECT imaging and comprehensive clinical assessment (MDS-UPDRS, Montreal Cognitive Assessment, constipation severity scales). Phase 2 (Months 13-18): Longitudinal monitoring with sample collection every 3 months to establish temporal relationships between microbiome changes and biomarker progression. Phase 3 (Months 19-36): Randomized, double-blind, placebo-controlled intervention trial. Stratify participants based on dysbiosis severity and randomize to receive either personalized probiotic therapy (containing Lactobacillus plantarum, Bifidobacterium longum, and Akkermansia muciniphila at 10^10 CFU daily) or matched placebo for 18 months. Continue monthly biomarker monitoring and quarterly clinical assessments. Phase 4 (Months 37-42): Post-intervention follow-up to assess sustainability of microbiome changes and clinical benefits. Statistical analysis will employ mixed-effects models accounting for repeated measures, with correction for multiple comparisons using false discovery rate methodology.
Expected Outcomes
Prodromal and early PD patients will demonstrate significant gut microbiome dysbiosis with 40-60% reduction in beneficial bacteria (Lachnospiraceae, Faecalibacterium) and 2-3 fold increase in pro-inflammatory species (Enterobacteriaceae) compared to controls (p<0.001).
Fecal α-synuclein levels will be elevated 3-5 fold in PD patients versus controls, with strong correlation (r>0.7) between microbiome dysbiosis severity and α-synuclein concentration.
Vagus nerve structural integrity will show progressive deterioration correlating with gut-brain biomarker progression, with 15-25% reduction in nerve fiber density in PD patients.
Personalized probiotic intervention will restore microbiome diversity (Shannon index improvement of 0.8-1.2 units) and reduce fecal α-synuclein by 30-50% compared to placebo group (p<0.01).
Clinical motor progression (MDS-UPDRS Part III) will be slowed by 40-60% in the intervention group over 18 months compared to placebo, with effect size Cohen's d = 0.6-0.8.
Dopaminergic function decline measured by DaTscan will be reduced by 25-40% in intervention participants, demonstrating neuroprotective effects of microbiome modulation.
Success Criteria
• Demonstrate statistically significant microbiome dysbiosis in PD patients with effect size >0.8 and establish clear temporal relationship with α-synuclein pathology (p<0.001)
• Achieve >80% participant retention through 42-month study period with complete biomarker datasets for primary endpoint analysis
• Show clinically meaningful slowing of motor progression (≥30% reduction in MDS-UPDRS Part III progression rate) in intervention group versus placebo
• Establish gut-brain biomarker panel with ≥85% sensitivity and ≥80% specificity for early PD detection and progression monitoring
• Demonstrate sustained microbiome restoration (≥6 months post-intervention) with continued clinical benefits in treatment responders
• Achieve primary endpoint significance with probiotic intervention showing ≥25% reduction in composite progression score (microbiome + clinical + imaging markers) compared to placebo (p<0.05)
TARGET GENE
AHR/BDNF/CLDN1
MODEL SYSTEM
human
ESTIMATED COST
$5,460,000
TIMELINE
45 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Intervention
Phase 1 (Months 1-12): Recruit and characterize 400 participants (n=150 prodromal PD, n=150 early PD, n=100 controls). Collect baseline fecal samples for 16S rRNA and metagenomic sequencing using Illumina NovaSeq platform. Quantify α-synuclein levels in stool and plasma via Simoa ultrasensitive immunoassays. Perform structural and functional MRI including vagus nerve tractography and substantia nigra neuromelanin imaging. Conduct DaTscan SPECT imaging and comprehensive clinical assessment (MDS-UPDRS, Montreal Cognitive Assessment, constipation severity scales). Phase 2 (Months 13-18): Longitudinal monitoring with sample collection every 3 months to establish temporal relationships between microbiome changes and biomarker progression.
...
Phase 1 (Months 1-12): Recruit and characterize 400 participants (n=150 prodromal PD, n=150 early PD, n=100 controls). Collect baseline fecal samples for 16S rRNA and metagenomic sequencing using Illumina NovaSeq platform. Quantify α-synuclein levels in stool and plasma via Simoa ultrasensitive immunoassays. Perform structural and functional MRI including vagus nerve tractography and substantia nigra neuromelanin imaging. Conduct DaTscan SPECT imaging and comprehensive clinical assessment (MDS-UPDRS, Montreal Cognitive Assessment, constipation severity scales). Phase 2 (Months 13-18): Longitudinal monitoring with sample collection every 3 months to establish temporal relationships between microbiome changes and biomarker progression. Phase 3 (Months 19-36): Randomized, double-blind, placebo-controlled intervention trial. Stratify participants based on dysbiosis severity and randomize to receive either personalized probiotic therapy (containing Lactobacillus plantarum, Bifidobacterium longum, and Akkermansia muciniphila at 10^10 CFU daily) or matched placebo for 18 months. Continue monthly biomarker monitoring and quarterly clinical assessments. Phase 4 (Months 37-42): Post-intervention follow-up to assess sustainability of microbiome changes and clinical benefits. Statistical analysis will employ mixed-effects models accounting for repeated measures, with correction for multiple comparisons using false discovery rate methodology.
Expected Outcomes
Prodromal and early PD patients will demonstrate significant gut microbiome dysbiosis with 40-60% reduction in beneficial bacteria (Lachnospiraceae, Faecalibacterium) and 2-3 fold increase in pro-inflammatory species (Enterobacteriaceae) compared to controls (p<0.001).
Fecal α-synuclein levels will be elevated 3-5 fold in PD patients versus controls, with strong correlation (r>0.7) between microbiome dysbiosis severity and α-synuclein concentration.
Vagus nerve structural integrity will show progressive deterioration correlating with gut-brain biomarker progression, with 15-25% reduction
...
Prodromal and early PD patients will demonstrate significant gut microbiome dysbiosis with 40-60% reduction in beneficial bacteria (Lachnospiraceae, Faecalibacterium) and 2-3 fold increase in pro-inflammatory species (Enterobacteriaceae) compared to controls (p<0.001).
Fecal α-synuclein levels will be elevated 3-5 fold in PD patients versus controls, with strong correlation (r>0.7) between microbiome dysbiosis severity and α-synuclein concentration.
Vagus nerve structural integrity will show progressive deterioration correlating with gut-brain biomarker progression, with 15-25% reduction in nerve fiber density in PD patients.
Personalized probiotic intervention will restore microbiome diversity (Shannon index improvement of 0.8-1.2 units) and reduce fecal α-synuclein by 30-50% compared to placebo group (p<0.01).
Clinical motor progression (MDS-UPDRS Part III) will be slowed by 40-60% in the intervention group over 18 months compared to placebo, with effect size Cohen's d = 0.6-0.8.
Dopaminergic function decline measured by DaTscan will be reduced by 25-40% in intervention participants, demonstrating neuroprotective effects of microbiome modulation.
Success Criteria
• Demonstrate statistically significant microbiome dysbiosis in PD patients with effect size >0.8 and establish clear temporal relationship with α-synuclein pathology (p<0.001)
• Achieve >80% participant retention through 42-month study period with complete biomarker datasets for primary endpoint analysis
• Show clinically meaningful slowing of motor progression (≥30% reduction in MDS-UPDRS Part III progression rate) in intervention group versus placebo
• Establish gut-brain biomarker panel with ≥85% sensitivity and ≥80% specificity for early PD detection and progression monitoring
•
...
• Demonstrate statistically significant microbiome dysbiosis in PD patients with effect size >0.8 and establish clear temporal relationship with α-synuclein pathology (p<0.001)
• Achieve >80% participant retention through 42-month study period with complete biomarker datasets for primary endpoint analysis
• Show clinically meaningful slowing of motor progression (≥30% reduction in MDS-UPDRS Part III progression rate) in intervention group versus placebo
• Establish gut-brain biomarker panel with ≥85% sensitivity and ≥80% specificity for early PD detection and progression monitoring
• Demonstrate sustained microbiome restoration (≥6 months post-intervention) with continued clinical benefits in treatment responders
• Achieve primary endpoint significance with probiotic intervention showing ≥25% reduction in composite progression score (microbiome + clinical + imaging markers) compared to placebo (p<0.05)